Sodium Butyrate in The Treatment of Irritable Bowel Syndrome KG
DOI:
https://doi.org/10.12775/QS.2025.40.59419Keywords
sodium butyrate, irritable bowel syndrome, butyric acid, SCFAsAbstract
Purpose of the research:
The purpose of this study is to present current knowledge on the use of sodium butyrate in the treatment of irritable bowel syndrome (IBS), with a particular focus on its effects on the microbiota and intestinal barrier.
Material and Methods:
The study is based on a review of the scientific literature, including clinical and experimental studies on the effects of sodium butyrate on the gastrointestinal tract.
Results:
Sodium butyrate strengthens the intestinal barrier, exhibits anti-inflammatory effects and influences the microbiota. Clinical studies confirm that its supplementation reduces abdominal pain, improves bowel rhythm and reduces bloating in IBS patients, resulting in a better quality of life.
Conclusions:
Sodium butyrate has the potential to be an effective support for IBS therapy, but further research is needed to determine its long-term safety and optimal dosage. In addition, changes in faecal levels of short-chain fatty acids (SCFAs) may act as a potential biomarker for IBS, but extra studies are needed to confirm their diagnostic value and define accurate reference levels.
References
1. Zhang, J., Li, M., & Liu, Y. (2017). The effects of butyrate on inflammatory bowel disease: A systematic review. Clinical Nutrition, 36(6), 1498-1507. https://doi.org/10.1016/j.clnu.2016.10.019
2. Liu, H., Wang, J., He, T., Becker, S., Zhang, G., Li, D., & Ma, X. (2018). Butyrate: A Double-Edged Sword for Health?. Advances in nutrition (Bethesda, Md.), 9(1), 21–29. https://doi.org/10.1093/advances/nmx009
3. Lewandowski K, Kaniewska M, Karłowicz K, Rosołowski M, Rydzewska G. The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Prz Gastroenterol. 2022;17(1):28-34. https://doi.org/10.5114/pg.2021.112681
4. Banasiewicz T, Borycka-Kiciak K, Kiciak A, et al. Butyric acid in bowel inflammations. Gastroenterology Review/Przegląd Gastroenterologiczny. 2010;5(5):251-257. https://doi.org/10.5114/pg.2010.17261
5. Majka Z, Zapala B, Krawczyk A, et al. Direct oral and fiber-derived butyrate supplementation as an anti-obesity treatment via different targets. Clin Nutr. 2024;43(3):869-880. https://doi.org/10.1016/j.clnu.2024.02.009
6. Pietrzak A, Banasiuk M, Szczepanik M, et al. Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases-Randomized Placebo-Controlled Multicenter Trial. Nutrients. 2022;14(16):3283. Published 2022 Aug 11. https://doi.org/10.3390/nu14163283
7. Recharla N, Geesala R, Shi XZ. Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review. Nutrients. 2023;15(10):2275. Published 2023 May 11. https://doi.org/10.3390/nu15102275
8. Facchin S, Vitulo N, Calgaro M, et al. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterol Motil. 2020;32(10):e13914. https://doi.org/10.1111/nmo.13914
9. Skrzydło-Radomańska B. Butyric acid - use in clinical practice. Lekarz POZ. 2019;1:67-68
10. Chen G, Ran X, Li B, et al. Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model. EBioMedicine.2018;30:317-325. https://doi.org/10.1016/j.ebiom.2018.03.030
11. Ng QX, Soh AYS, Loke W, Lim DY, Yeo WS. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res. 2018;11:345-349. Published 2018 Sep 21. https://doi.org/10.2147/JIR.S174982
12. Dothel G, Barbaro MR, Di Vito A, et al. New insights into irritable bowel syndrome pathophysiological mechanisms: contribution of epigenetics. J Gastroenterol. 2023;58(7):605-621. https://doi.org/10.1007/s00535-023-01997-6
13. Kaźmierczak-Siedlecka K, Marano L, Merola E, Roviello F, Połom K. Sodium butyrate in both prevention and supportive treatment of colorectal cancer. Front Cell Infect Microbiol. 2022;12:1023806. Published 2022 Oct 26. https://doi.org/10.3389/fcimb.2022.1023806
14. Pietrzak A, Banasiewicz T. Applicability of sodium butyrate preparations from a surgeon’s and gastroenterologist’s perspective. Pol Przegl Chir. (2024);96(2):68-73. https://doi.org/10.5604/01.3001.0054.4152
15. Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44. https://doi.org/10.14309/ajg.0000000000001036
16. Pietrzak A, Skrzydło-Radomańska B, Mulak A, et al. Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik. Prz Gastroenterol. 2018;13(4):259-288. https://doi.org/10.5114/pg.2018.78343
17. Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. Gastroenterology. 2022;163(1):118-136. https://doi.org/10.1053/j.gastro.2022.04.016
18. Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. Gastroenterology. 2022;163(1):137-151. https://doi.org/10.1053/j.gastro.2022.04.017
19. Huang KY, Wang FY, Lv M, Ma XX, Tang XD, Lv L. Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment. World J Gastroenterol. 2023;29(26):4120-4135. https://doi.org/10.3748/wjg.v29.i26.4120
20. Wollny T, Daniluk T, Piktel E, et al. Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome. Pathogens. 2021;10(12):1545. Published 2021 Nov 25. https://doi.org/10.3390/pathogens10121545
21. Radziszewska M, Smarkusz-Zarzecka J, Ostrowska L. Nutrition, Physical Activity and Supplementation in Irritable Bowel Syndrome. Nutrients. 2023;15(16):3662. Published 2023 Aug 21. https://doi.org/10.3390/nu15163662
22. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257-1261. https://doi.org/10.1053/j.gastro.2016.03.035
23. Gąsiorowska A, Romanowski M, Walecka-Kapica E, Kaczka A, Chojnacki C, Padysz M, Siedlecka M, Bierła JB, Steinert RE, Cukrowska B. Effects of Microencapsulated Sodium Butyrate, Probiotics and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome: A Study Protocol of a Randomized Double-Blind Placebo-Controlled Trial. Journal of Clinical Medicine. 2022; 11(21):6587. https://doi.org/10.3390/jcm11216587
24. Borycka-Kiciak K, Banasiewicz T, Rydzewska G. Butyric acid - a well-known molecule revisited. Prz Gastroenterol. 2017;12(2):83-89. https://doi.org/10.5114/pg.2017.68342
25. Pozuelo M, Panda S, Santiago A, et al. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci Rep. 2015;5:12693. Published 2015 Aug 4. https://doi.org/10.1038/srep12693
26. Banasiewicz T, Krokowicz Ł, Stojcev Z, et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis. 2013;15(2):204-209. https://doi.org/10.1111/j.1463-1318.2012.03152.x
27. Tarnowski W, Borycka-Kiciak K, Kiciak A i wsp. Results of treatment of irritable bowel syndrome with butyric acid - preliminary report. Gastroenterol Prakt 2011;1:43-8.
28. Rettura F, Lambiase C, Grosso A, et al. Role of Low-FODMAP diet in functional dyspepsia: "Why", "When", and "to Whom". Best Pract Res Clin Gastroenterol. 2023;62-63:101831. https://doi.org/10.1016/j.bpg.2023.101831
29. Sun Q, Jia Q, Song L, Duan L. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(7):e14513. https://doi.org/10.1097/MD.0000000000014513
30. Farup, P.G., Rudi, K. & Hestad, K. Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome?. BMC Gastroenterol 16, 51 (2016). https://doi.org/10.1186/s12876-016-0446-z
31. Kim JH, Lin E, Pimentel M. Biomarkers of Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2017;23(1):20-26. https://doi.org/10.5056/jnm16135
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Karolina Grabowska, Martyna Grabowska, Aleksandra Wiśniewska, Jakub Dąbek, Wiktoria Kosucka, Dominik Balik, Joanna Lara, Anna Kwaśniewska, Karolina Kaszyńska, Jagoda Kubicka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 167
Number of citations: 0
